Pan‐pox‐specific T‐cell responses in HIV‐1‐infected individuals after JYNNEOS vaccination

People living with human immunodeficiency virus (HIV) are the individuals most affected by the current Monkeypox virus outbreak that was first announced in May 2022. Here we report Pan‐pox‐specific T‐cell responses in a cohort of HIV‐1‐infected individuals after receiving the nonreplicative, attenuated smallpox vaccine JYNNEOS from Bavarian Nordic. Intradermal (i.d.) and subcutaneous (s.c.) vaccination was safe without major side effects. Dose‐sparing i.d. vaccination was superior to s.c. vaccination and promoted T‐cell polyfunctionality, and the expression of the gut‐homing marker α4β7 integrin on lymphocytes. HIV‐1‐infected individuals with CD4 T‐cell counts ≤500/mm3 blood required at least a booster vaccination to exhibit efficient virus‐specific T‐cell responses. The magnitude of the Th1 response after this booster directly correlated with the CD4 T‐cell count of the vaccinees. Further studies with a larger number of participants are warranted to confirm and expand our observations.